

Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/G507E3FF9C60EN.html>

Date: September 2024

Pages: 115

Price: US\$ 3,200.00 (Single User License)

ID: G507E3FF9C60EN

Abstracts

Report Overview:

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.

Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.

The Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Size was estimated at USD 5643.47 million in 2023 and is projected to reach USD 7649.63 million by 2029, exhibiting a CAGR of 5.20% during the forecast period.

This report provides a deep insight into the global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics market in any manner.

Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Astellas Inc.

Johnson & Johnson

Sanofi S.A

Dendreon Corporation

Bayer AG

Market Segmentation (by Type)

Oral Therapy

Injectable Therapy

Market Segmentation (by Application)

Hospitals & Clinics

Home Settings

Ambulatory Surgical Centers (ASCs)

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market

Overview of the regional outlook of the Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market and its

likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics

1.2 Key Market Segments

1.2.1 Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Segment by Type

1.2.2 Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND HRPDA THERAPEUTICS MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2030)

2.1.2 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Estimates and Forecasts (2019-2030)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND HRPDA THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

3.1 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales by Manufacturers (2019-2024)

3.2 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Revenue Market Share by Manufacturers (2019-2024)

3.3 Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics

Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Sales Sites, Area Served, Product Type

3.6 Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Competitive Situation and Trends

3.6.1 Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Concentration Rate

3.6.2 Global 5 and 10 Largest Castration-Resistant Prostate Cancer (CRPC) and
HRPCA Therapeutics Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND HRP CA THERAPEUTICS INDUSTRY CHAIN ANALYSIS

4.1 Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND HRP CA THERAPEUTICS MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

6 CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND HRP CA THERAPEUTICS MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics

Sales Market Share by Type (2019-2024)

6.3 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Size Market Share by Type (2019-2024)

6.4 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Price by Type (2019-2024)

7 CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND HRPDA THERAPEUTICS MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Sales by Application (2019-2024)

7.3 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Size (M USD) by Application (2019-2024)

7.4 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Growth Rate by Application (2019-2024)

8 CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND HRPDA THERAPEUTICS MARKET SEGMENTATION BY REGION

8.1 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales by Region

8.1.1 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales by Region

8.1.2 Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Market Share by Region

8.2 North America

8.2.1 North America Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Castration-Resistant Prostate Cancer (CRPC) and HRP

Therapeutics Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Castration-Resistant Prostate Cancer (CRPC) and HRP

Therapeutics Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) and HRP
Therapeutics Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Astellas Inc.

9.1.1 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) and HRP
Therapeutics Basic Information

9.1.2 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) and HRP
Therapeutics Product Overview

9.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) and HRP
Therapeutics Product Market Performance

9.1.4 Astellas Inc. Business Overview

9.1.5 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) and HRP
Therapeutics SWOT Analysis

9.1.6 Astellas Inc. Recent Developments

9.2 Johnson and Johnson

9.2.1 Johnson and Johnson Castration-Resistant Prostate Cancer (CRPC) and

HRPCA Therapeutics Basic Information

9.2.2 Johnson and Johnson Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Overview

9.2.3 Johnson and Johnson Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Market Performance

9.2.4 Johnson and Johnson Business Overview

9.2.5 Johnson and Johnson Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics SWOT Analysis

9.2.6 Johnson and Johnson Recent Developments

9.3 Sanofi S.A

9.3.1 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Basic Information

9.3.2 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Overview

9.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Market Performance

9.3.4 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics SWOT Analysis

9.3.5 Sanofi S.A Business Overview

9.3.6 Sanofi S.A Recent Developments

9.4 Dendreon Corporation

9.4.1 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Basic Information

9.4.2 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Overview

9.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Market Performance

9.4.4 Dendreon Corporation Business Overview

9.4.5 Dendreon Corporation Recent Developments

9.5 Bayer AG

9.5.1 Bayer AG Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Basic Information

9.5.2 Bayer AG Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Overview

9.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Market Performance

9.5.4 Bayer AG Business Overview

9.5.5 Bayer AG Recent Developments

10 CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND HRP CA THERAPEUTICS MARKET FORECAST BY REGION

10.1 Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Size Forecast

10.2 Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Forecast by Region

10.2.1 North America Market Size Forecast by Country

10.2.2 Europe Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Size Forecast by Country

10.2.3 Asia Pacific Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Size Forecast by Region

10.2.4 South America Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Size Forecast by Country

10.2.5 Middle East and Africa Forecasted Consumption of Castration-Resistant
Prostate Cancer (CRPC) and HRP
CA Therapeutics by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)

11.1 Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Forecast by Type (2025-2030)

11.1.1 Global Forecasted Sales of Castration-Resistant Prostate Cancer (CRPC) and
HRP
CA Therapeutics by Type (2025-2030)

11.1.2 Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Size Forecast by Type (2025-2030)

11.1.3 Global Forecasted Price of Castration-Resistant Prostate Cancer (CRPC) and
HRP
CA Therapeutics by Type (2025-2030)

11.2 Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Forecast by Application (2025-2030)

11.2.1 Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Sales (K Units) Forecast by Application

11.2.2 Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Size (M USD) Forecast by Application (2025-2030)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

- Table 1. Introduction of the Type
- Table 2. Introduction of the Application
- Table 3. Market Size (M USD) Segment Executive Summary
- Table 4. Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Size Comparison by Region (M USD)
- Table 5. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales (K Units) by Manufacturers (2019-2024)
- Table 6. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Market Share by Manufacturers (2019-2024)
- Table 7. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Revenue (M USD) by Manufacturers (2019-2024)
- Table 8. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Revenue Share by Manufacturers (2019-2024)
- Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics as of 2022)
- Table 10. Global Market Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Average Price (USD/Unit) of Key Manufacturers (2019-2024)
- Table 11. Manufacturers Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Sites and Area Served
- Table 12. Manufacturers Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Product Type
- Table 13. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 14. Mergers & Acquisitions, Expansion Plans
- Table 15. Industry Chain Map of Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics
- Table 16. Market Overview of Key Raw Materials
- Table 17. Midstream Market Analysis
- Table 18. Downstream Customer Analysis
- Table 19. Key Development Trends
- Table 20. Driving Factors
- Table 21. Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Challenges
- Table 22. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales by Type (K Units)

- Table 23. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Size by Type (M USD)
- Table 24. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales (K Units) by Type (2019-2024)
- Table 25. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Market Share by Type (2019-2024)
- Table 26. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Size (M USD) by Type (2019-2024)
- Table 27. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Size Share by Type (2019-2024)
- Table 28. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Price (USD/Unit) by Type (2019-2024)
- Table 29. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales (K Units) by Application
- Table 30. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Size by Application
- Table 31. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales by Application (2019-2024) & (K Units)
- Table 32. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Market Share by Application (2019-2024)
- Table 33. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales by Application (2019-2024) & (M USD)
- Table 34. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Share by Application (2019-2024)
- Table 35. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Growth Rate by Application (2019-2024)
- Table 36. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales by Region (2019-2024) & (K Units)
- Table 37. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Market Share by Region (2019-2024)
- Table 38. North America Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales by Country (2019-2024) & (K Units)
- Table 39. Europe Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales by Country (2019-2024) & (K Units)
- Table 40. Asia Pacific Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales by Region (2019-2024) & (K Units)
- Table 41. South America Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales by Country (2019-2024) & (K Units)
- Table 42. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) and

HRPCA Therapeutics Sales by Region (2019-2024) & (K Units)

Table 43. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Basic Information

Table 44. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Overview

Table 45. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 46. Astellas Inc. Business Overview

Table 47. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics SWOT Analysis

Table 48. Astellas Inc. Recent Developments

Table 49. Johnson and Johnson Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Basic Information

Table 50. Johnson and Johnson Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Overview

Table 51. Johnson and Johnson Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 52. Johnson and Johnson Business Overview

Table 53. Johnson and Johnson Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics SWOT Analysis

Table 54. Johnson and Johnson Recent Developments

Table 55. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Basic Information

Table 56. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Overview

Table 57. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 58. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics SWOT Analysis

Table 59. Sanofi S.A Business Overview

Table 60. Sanofi S.A Recent Developments

Table 61. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Basic Information

Table 62. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Overview

Table 63. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) and

HRPCA Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 64. Dendreon Corporation Business Overview

Table 65. Dendreon Corporation Recent Developments

Table 66. Bayer AG Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Basic Information

Table 67. Bayer AG Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Product Overview

Table 68. Bayer AG Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 69. Bayer AG Business Overview

Table 70. Bayer AG Recent Developments

Table 71. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Forecast by Region (2025-2030) & (K Units)

Table 72. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)

Table 73. North America Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Forecast by Country (2025-2030) & (K Units)

Table 74. North America Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)

Table 75. Europe Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Forecast by Country (2025-2030) & (K Units)

Table 76. Europe Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)

Table 77. Asia Pacific Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Forecast by Region (2025-2030) & (K Units)

Table 78. Asia Pacific Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)

Table 79. South America Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Forecast by Country (2025-2030) & (K Units)

Table 80. South America Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)

Table 81. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Consumption Forecast by Country (2025-2030) & (Units)

Table 82. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)

Table 83. Global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Forecast by Type (2025-2030) & (K Units)

Table 84. Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Size Forecast by Type (2025-2030) & (M USD)

Table 85. Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Price Forecast by Type (2025-2030) & (USD/Unit)

Table 86. Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Sales (K Units) Forecast by Application (2025-2030)

Table 87. Global Castration-Resistant Prostate Cancer (CRPC) and HRP
CA Therapeutics Market Size Forecast by Application (2025-2030) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Size (M USD), 2019-2030

Figure 5. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Size (M USD) (2019-2030)

Figure 6. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales (K Units) & (2019-2030)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Size by Country (M USD)

Figure 11. Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Share by Manufacturers in 2023

Figure 12. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Revenue Share by Manufacturers in 2023

Figure 13. Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Average Price (USD/Unit) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Share by Type

Figure 18. Sales Market Share of Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics by Type (2019-2024)

Figure 19. Sales Market Share of Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics by Type in 2023

Figure 20. Market Size Share of Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics by Type (2019-2024)

Figure 21. Market Size Market Share of Castration-Resistant Prostate Cancer (CRPC)

and HRPDA Therapeutics by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Share by Application

Figure 24. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Market Share by Application (2019-2024)

Figure 25. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Market Share by Application in 2023

Figure 26. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Share by Application (2019-2024)

Figure 27. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Share by Application in 2023

Figure 28. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Growth Rate by Application (2019-2024)

Figure 29. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Market Share by Region (2019-2024)

Figure 30. North America Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Market Share by Country in 2023

Figure 32. U.S. Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Market Share by Country in 2023

Figure 37. Germany Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Castration-Resistant Prostate Cancer (CRPC) and HRPDA

Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Market Share by Region in 2023

Figure 44. China Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (K Units)

Figure 50. South America Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Market Share by Country in 2023

Figure 51. Brazil Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Forecast by Volume (2019-2030) & (K Units)

Figure 62. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Size Forecast by Value (2019-2030) & (M USD)

Figure 63. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Market Share Forecast by Type (2025-2030)

Figure 64. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Share Forecast by Type (2025-2030)

Figure 65. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Sales Forecast by Application (2025-2030)

Figure 66. Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Castration-Resistant Prostate Cancer (CRPC) and HRPDA Therapeutics Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/G507E3FF9C60EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G507E3FF9C60EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

